Otonomy (OTIC) Provides Update on Clinical Trials, Development Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Otonomy Provides Update on Clinical Trials and Development Programs
June 15, 2020 4:05 PM EDTResults from Phase 3 trial of OTIVIDEX® in Ménières disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020Current capital funds operations through all clinical trial readouts
Conference call and webcast today at 4:30 p.m. ET
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Otonomy,... More



